Yes, St. John's wort causes clinically significant drug interactions, and they are well documented, not theoretical. It speeds up the breakdown of many prescription medicines by revving up liver and gut enzymes, and it can push serotonin to dangerous levels when mixed with certain antidepressants. If you take any prescription medication, tell your doctor and pharmacist before starting it, and never combine it with high-risk drugs like immunosuppressants, blood thinners, or SSRIs without direct supervision.
TL;DR:
- St. John's wort significantly interacts with immunosuppressants, antiretrovirals, and narrow therapeutic drugs by accelerating drug metabolism, risking organ rejection or treatment failure.
- Hyperforin content varies widely in products, with higher levels causing stronger enzyme induction and lower levels possibly reducing interaction risks but never eliminating them.
- The induction of CYP3A4 and P-glycoprotein takes one to two weeks to develop and two to three weeks to diminish after stopping, affecting timing around procedures or new prescriptions.
- Combining St. John's wort with serotonergic drugs increases the risk of serotonin syndrome through additive effects, not metabolism, requiring careful monitoring.
- Always consult healthcare providers and verify medication interactions before starting St. John's wort, especially if on high-risk medications like transplant drugs, blood thinners, or contraceptives.
Table of Contents
- Which Medications Interact With St. John's Wort?
- How Does St. John's Wort Cause These Interactions?
- Does Hyperforin Content Change the Risk Level?
- What Do Real Case Reports Show?
- What Should You Do Before Taking St. John's Wort?
- Do Other Supplements or Foods Change the Risk?
- How Do You Check for Interactions Before Taking St. John's Wort?
- A Clinician-Minded Take on Where This Goes Wrong
- Verify Before You Combine: NutraSmarts' Ingredient Tools
- Where to Read More on This Topic
- Sources
- FAQ
Which Medications Interact With St. John's Wort?
St. John's wort does not interact with everything equally. It hits certain drug classes hard, and the reason has to do with how those drugs get processed and how narrow their safety margin is. A drug with a wide therapeutic window can tolerate some interference. A drug with a razor-thin margin between "working" and "dangerous" cannot.
Here is the prioritized rundown of what to watch for, based on the clinical pharmacology literature and NCCIH's official guidance:
- Immunosuppressants (cyclosporine, tacrolimus): St. John's wort lowers blood levels of these drugs enough to trigger organ transplant rejection. This is arguably the single most dangerous interaction on this list because the consequence is irreversible organ loss, not just a symptom flare.
- Oral contraceptives: Reduced hormone levels mean reduced contraceptive effectiveness. Women have reported breakthrough bleeding and unintended pregnancy while taking St. John's wort alongside birth control pills.
- Anticoagulants (warfarin): St. John's wort throws off INR readings unpredictably. Depending on timing and dose, a patient can swing toward under-anticoagulation (clot risk) or, after stopping the herb, toward over-anticoagulation (bleeding risk).
- Antiretrovirals and protease inhibitors: HIV medications like indinavir lose potency, which risks viral rebound and resistance development. This interaction is serious enough that the FDA specifically flags it in its clinical guidance for providers.
- Antineoplastics (irinotecan, imatinib): Cancer drugs metabolized faster than intended mean lower drug exposure, which can translate directly into reduced tumor response.
- Anticonvulsants and certain benzodiazepines: Levels drop enough to compromise seizure control in some patients, and sedative effects from benzodiazepines like alprazolam can become less predictable.
- Statins (simvastatin) and select cardiac drugs: Cholesterol control weakens when statin levels fall, and some cardiac medications, including digoxin, show altered blood concentrations that complicate dosing.
- Serotonergic agents (SSRIs, SNRIs, triptans): This is the outlier on the list because the mechanism is different. Instead of a metabolism problem, you get an additive effect, too much serotonin activity, which raises the risk of serotonin syndrome.
The clinical review by Nicolussi and colleagues lists digoxin, tacrolimus, indinavir, warfarin, alprazolam, simvastatin, and oral contraceptives by name as drugs with documented pharmacokinetic interactions. That is not a hypothetical list. Every one of those has case reports or controlled pharmacokinetic studies behind it.
Notice the pattern: most of these interactions cause a drug to work less well, not more. That is counterintuitive for a lot of people, who assume "herbal supplement plus medication" means an overdose risk. With St. John's wort, the more common danger is silent treatment failure. Mayo Clinic's patient guidance singles out antidepressants specifically, warning that combining them with St. John's wort can push serotonin levels too high, the one major exception where the herb adds an effect rather than erasing one.
How Does St. John's Wort Cause These Interactions?
St. John's wort works through two completely separate mechanisms, and understanding which one applies to your medication tells you what kind of risk you are actually facing.
The first mechanism, and the one responsible for most of the drug interaction list above, involves a compound in the plant called hyperforin. Hyperforin activates a receptor in liver and intestinal cells called the pregnane X receptor, or PXR. Once PXR gets switched on, it ramps up production of CYP3A4, a liver enzyme responsible for metabolizing roughly half of all prescription drugs on the market. It also ramps up P-glycoprotein, a transporter protein that pumps drugs out of intestinal cells before they can even get absorbed into the bloodstream. The net effect: drugs get broken down faster and absorbed less efficiently, so less active drug reaches its target. NCCIH confirms this induction of CYP3A4 and P-glycoprotein as the central mechanism behind most of St. John's wort's documented interactions.
This is not an instant switch. Enzyme induction takes time to build, typically one to two weeks of regular use before the effect becomes clinically meaningful, according to the pharmacokinetic literature. It also takes time to fade after you stop. Because the body has to synthesize new enzyme protein down and gradually reduce it, plasma levels of affected medications do not snap back to normal the day you quit St. John's wort. They drift back over roughly two to three weeks. That lag matters enormously for anyone planning a surgery, starting a new prescription, or transitioning off the herb, because "I stopped last week" does not mean the interaction is over.
The second mechanism is entirely different and has nothing to do with metabolism. St. John's wort has mild serotonergic activity of its own, likely tied to hypericin and related compounds. When you add that to a drug that already boosts serotonin, an SSRI, an SNRI, a triptan for migraines, even certain over-the-counter cold remedies, the effects stack rather than cancel out. That stacking is what causes serotonin syndrome: agitation, rapid heart rate, high blood pressure, muscle rigidity, and in severe cases, fever and seizures.
Why do narrow therapeutic index drugs get hit hardest? Because those are the drugs where a modest percentage drop in blood level is the difference between "therapeutic" and "subtherapeutic." Cyclosporine and warfarin do not have much room to give. A drug like ibuprofen, with a wide margin between an effective dose and a harmful one, could theoretically have its metabolism altered too, but nobody would notice or care.
Does Hyperforin Content Change the Risk Level?
Hyperforin dose is a key variable influencing the interaction risk of St. John's wort products, and it varies widely between commercial extracts. Two bottles labeled "St. John's wort 300 mg" can carry wildly different hyperforin content depending on the plant extraction method, harvest conditions, and standardization process used by the manufacturer.
Research summarized in the pharmacokinetics literature on hyperforin content shows a clear dose relationship: as daily hyperforin exposure rises, so does the magnitude of CYP3A4 induction and the resulting drop in co-medication blood levels. This is not a binary "interacts or doesn't" situation. It is a dial, and the hyperforin content sets how far that dial gets turned.
The Ze117 Finding: A phase I study testing a low-hyperforin extract called Ze117 found no clinically relevant induction of major CYP enzymes or P-glycoprotein when tested against probe drugs, a result that stands in sharp contrast to high-hyperforin extracts tested in earlier studies. Researchers reported the finding in a controlled pharmacokinetic trial.
That is a meaningful signal, but it comes with real caveats. The Ze117 study tested probe drugs under controlled conditions. It did not test every high-risk medication class, and "minimal induction in this trial" is not the same as "safe to combine with your transplant medication." Here is how hyperforin exposure tends to break down across preparation types:
| Extract Type | Approximate Hyperforin Level | Interaction Signal in Studies |
|---|---|---|
| High-hyperforin standardized extract | Higher daily hyperforin dose | Strong CYP3A4/P-gp induction, significant co-medication level drops |
| Low-hyperforin extract (e.g., Ze117) | Low daily hyperforin dose | No clinically relevant induction detected in probe-drug testing |
| Unstandardized or inconsistently labeled products | Unknown, batch-dependent | Unpredictable; cannot be assumed low-risk |
The practical problem is that most consumer labels do not tell you the hyperforin content at all, they tell you the total extract weight or a generic "standardized to hypericin" claim, which is a different compound entirely. Batch-to-batch variability compounds the issue further. A product tested once in a lab is not a guarantee that the bottle on the shelf next month matches that formulation exactly.
The practical rule that follows from all this: a low-hyperforin product may carry lower interaction risk, but "lower" is not "zero," and it is never a substitute for clinician supervision if you are on a high-risk medication. Nobody should read the Ze117 data as a green light to mix any St. John's wort product with cyclosporine or warfarin.
What Do Real Case Reports Show?
The clearest way to understand this risk is to look at what has actually happened to patients, not just what enzyme kinetics predict on paper.
Transplant medicine has produced some of the most sobering examples. Multiple case reports describe organ transplant recipients who started taking St. John's wort, saw their cyclosporine blood levels drop, and experienced acute rejection episodes, in some cases within weeks of starting the herb. The timeline lines up precisely with the induction period described earlier: levels fall gradually as CYP3A4 activity ramps up, and by the time a routine lab check catches the drop, rejection may already be underway.
Documented Impact: Clinical pharmacology reviews describe patients on stable immunosuppressant regimens experiencing organ rejection after adding St. John's wort, with drug levels falling low enough to lose therapeutic control, according to the clinical relevance review.
Oral contraceptive failures follow a similar pattern, just with lower individual stakes and higher frequency. John's wort alongside combined oral contraceptives, and case reports document breakthrough bleeding as the visible warning sign, followed in some instances by unintended pregnancy when women did not recognize the bleeding as a contraceptive failure signal.
Probe-drug studies, research using a test medication specifically to measure enzyme activity, have quantified some of these effects directly:
- Studies using midazolam as a CYP3A4 probe have shown measurably reduced drug exposure after regular St. John's wort use, consistent with strong enzyme induction.
- Cyclosporine pharmacokinetic studies in transplant patients have documented significant reductions in trough blood levels after St. John's wort initiation, the direct mechanism behind the rejection case reports above.
- Studies referenced in the Nicolussi clinical review list digoxin and indinavir among drugs with confirmed reduced blood levels during co-administration.
The real-world takeaway across all of these cases is the same: the interaction is often clinically silent right up until it isn't. A patient does not feel their cyclosporine level dropping. They feel fine, right up until the biopsy that confirms rejection, or the positive pregnancy test that reveals the contraceptive failure. That silence is exactly what makes disclosure and monitoring non-negotiable rather than optional.
What Should You Do Before Taking St. John's Wort?
If you take any prescription medication, especially anything from the high-risk list above, treat starting St. John's wort with the same seriousness as starting a new prescription drug. Here is the order of operations that actually protects you.
- Build a complete list first. Write out every prescription drug, over-the-counter medication, and supplement you currently take, including dose and frequency, and bring it to your prescriber or pharmacist before you buy St. John's wort. Pharmacists are underused here. Most can screen your list for CYP3A4 or P-glycoprotein conflicts in a few minutes, often faster than scheduling a doctor's appointment.
- Do not start or stop it on your own if you're on a high-risk medication. If you take an immunosuppressant, an anticoagulant, a hormonal contraceptive, an antiretroviral, or a seizure medication, get direct clinician guidance before making any change. Ask specifically about supervised alternatives if you are managing mood symptoms and want to avoid this whole category of risk.
- Set up monitoring if you proceed. For warfarin, that means more frequent INR checks in the weeks after starting or stopping St. John's wort, not just your usual schedule. For transplant medications, that means therapeutic drug monitoring your transplant team should already be doing, but flag the change explicitly. For contraception, that means pregnancy testing awareness and a conversation about backup contraception during the transition period.
- Plan timing around procedures and new prescriptions realistically. Because enzyme induction takes one to two weeks to build and two to three weeks to fully resolve after stopping, "I stopped it three days ago" does not mean your enzyme activity is back to baseline. Surgeons and anesthesiologists generally want St. John's wort stopped well in advance of a procedure, and starting a new high-risk prescription right after quitting the herb still carries residual interaction risk.
Pro Tip: Keep your medication list on your phone, not just in your head. When a pharmacist asks "are you taking anything else," people routinely forget supplements because they don't mentally file them as "medication." That blind spot is exactly how these interactions slip through.
Do Other Supplements or Foods Change the Risk?
A few supplement-specific questions come up constantly, and they deserve straight answers rather than vague reassurance.
Does St. John's wort lower cortisol? The evidence here is thin. Authoritative summaries have not established a meaningful cortisol-lowering effect from St. John's wort, and clinical attention stays focused on the drug interactions above rather than hormonal suppression. If you're worried about cortisol specifically, that is not where the real risk lives with this herb.
Does St. John's wort interact with magnesium? No meaningful pharmacokinetic interaction has been identified between the two. Magnesium is not metabolized through CYP3A4, so the induction mechanism driving most St. John's wort interactions simply doesn't apply here.
The bigger blind spot is combination products. Multi-ingredient sleep, mood, or stress formulas sometimes stack St. John's wort with other serotonergic botanicals, like 5-HTP or certain adaptogens, without making that combination obvious on the front label. Read the full ingredient panel, not just the headline ingredient, before assuming a product is a simple single-herb supplement.
It's worth contrasting St. John's wort with grapefruit, since people often lump "supplement and drug interactions" into one bucket. Grapefruit inhibits CYP3A4, which raises drug levels and risks toxicity. St. John's wort induces CYP3A4, which lowers drug levels and risks treatment failure. Opposite mechanisms, opposite direction of harm, and that distinction is exactly why generic "avoid grapefruit-type interactions" warnings don't map cleanly onto this herb.
How Do You Check for Interactions Before Taking St. John's Wort?
You do not have to take a supplement label's word for anything. A handful of authoritative resources let you verify interaction risk directly, and combining them with a clinician conversation gives you a genuinely evidence-based decision instead of a guess.
- FDA's CYP enzyme and transporter examples table lists St. John's wort explicitly as a strong CYP3A4 inducer, the same regulatory-grade reference prescribers and pharmacists use to flag risky combinations.
- NCCIH's patient-facing summary gives a plain-language overview of which drug classes are affected and why, useful as your first stop if you want the government's own consumer safety framing.
- The PMC clinical review by Nicolussi and colleagues goes deeper into mechanism and lists specific affected drugs by name, useful if you want the pharmacology behind a specific medication you take.
- NutraSmarts' St. John's wort ingredient profile aggregates the clinical citations behind hyperforin dosing and interaction evidence in one place, so you're not hunting across five separate journal articles to piece the picture together.
- NutraSmarts' Supplement Facts Tool helps you work backward from a product label to estimate actual hyperforin exposure, since most bottles don't state it directly.
A reasonable verification workflow looks like this: list every medication you take, identify which ones are known CYP3A4 or P-glycoprotein substrates using the FDA table above, cross-check that list against NCCIH and the clinical review, then bring the whole picture to your prescriber or pharmacist before you buy anything. Five minutes of checking beats a rejected transplant or a missed contraceptive dose.
A Clinician-Minded Take on Where This Goes Wrong
The biggest failure point in this entire topic isn't the pharmacology. It's disclosure. Patients routinely leave herbal supplements off their medication list because they don't think of a bottle from the health food aisle as "real medicine." With St. John's wort, that habit is genuinely dangerous, not just sloppy recordkeeping.
Clinicians share responsibility here too. A medication reconciliation that only asks "what prescriptions are you on" misses this entirely. Providers managing transplant patients, anyone on warfarin, or patients on hormonal contraception should be asking specifically about herbal and supplement use, and considering therapeutic drug monitoring when there's any chance of recent St. John's wort exposure.
If there's one habit worth building from this article, it's this: bring your full medication and supplement list, written out, to every single appointment. Not from memory. Written out. That one habit closes the exact gap that turns a manageable interaction into a rejected organ or a failed pregnancy test.
— NutraSmarts
Verify Before You Combine: NutraSmarts' Ingredient Tools
Reading a supplement label doesn't tell you the hyperforin dose, and no bottle on a shelf is going to volunteer its interaction profile. That's the gap NutraSmarts is built to close: an evidence-linked St. John's wort ingredient profile that pulls together the clinical citations behind hyperforin dosing and interaction risk, so you can see the actual research instead of a marketing claim on packaging.
Pair that with the free Supplement Facts Tool, which helps you work backward from a product's label to estimate real hyperforin exposure, the exact number most bottles never print. If you're managing a specific health concern and want to compare options with a similar evidence lens, NutraSmarts' symptom-based supplement directory covers alternatives across mood, sleep, and dozens of other categories. Run your product through the tool, print the results, and bring them to your next appointment before you start anything new.
Where to Read More on This Topic
The claims in this guide trace back to a small set of sources worth bookmarking if you want to go deeper on your own.
- NCCIH's St. John's wort summary gives the clearest patient-facing overview of safety concerns and affected drug classes.
- FDA's CYP and transporter examples table provides the regulatory context clinicians rely on for CYP3A4 and P-glycoprotein interactions.
- The Nicolussi clinical review offers the deepest mechanistic and clinical detail, including specific affected drugs.
- Mayo Clinic's patient guidance rounds out the picture with practical, everyday safety advice.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- St. John's Wort | NCCIH
- Clinical relevance of St. John's wort drug interactions revisited
- FDA: Examples of drugs that interact with CYP enzymes and transporter systems
- No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 low in hyperforin
- St. John's wort | Mayo Clinic
FAQ
What Medications Interact Badly With St. John's Wort?
Immunosuppressants like cyclosporine and tacrolimus top the list because reduced blood levels can trigger organ transplant rejection. Anticoagulants like warfarin, oral contraceptives, antiretrovirals, certain anticonvulsants, and antidepressants also carry documented, clinically significant interaction risk, according to the clinical relevance review.
What Can't You Combine With St. John's Wort?
Avoid combining it with SSRIs, SNRIs, and other serotonergic drugs without clinician supervision, since the combination raises serotonin syndrome risk. Also avoid combining it with narrow therapeutic index drugs like cyclosporine, warfarin, and hormonal contraceptives, where reduced blood levels can cause treatment failure, per NCCIH's guidance.
Does St. John's Wort Lower Cortisol?
There isn't strong evidence supporting a meaningful cortisol-lowering effect from St. John's wort. Clinical concern with this herb centers on drug metabolism and serotonergic interactions, not hormonal suppression.
Does St. John's Wort Interact With Magnesium?
No significant pharmacokinetic interaction has been identified between St. John's wort and magnesium. The bigger concern is multi-ingredient supplements that combine St. John's wort with other serotonergic ingredients without clearly labeling that combination.
Does Low-Hyperforin St. John's Wort Reduce Interaction Risk?
Yes, research on the low-hyperforin extract Ze117 found no clinically relevant induction of major CYP enzymes in probe-drug testing, unlike high-hyperforin extracts, according to a controlled pharmacokinetic study. That said, lower risk isn't zero risk, and high-risk medications still warrant clinician supervision regardless of hyperforin content.